Healthy astrocytes secrete clusterin, a chaperone glycoprotein that prevents stress-induced protein aggregation and stabilizes TDP-43 solubility. Clusterin may act as a broad extracellular chaperone supporting protein homeostasis rather than a precise RBP-trafficking switch. VCP-mutant astrocytes show impaired secretome function that reduces clusterin release, preventing protection against proteostasis stress. The hypothesis is best considered a discovery node: identifying downstream protective pathways is more tractable than delivering the full protein.
Curated pathway from expert analysis
flowchart TD
A["CLU (APOJ); VCP<br/>Primary Target"]
B["Biological Process 1<br/>Mechanistic Step A"]
C["Biological Process 2<br/>Mechanistic Step B"]
D["Output Phenotype<br/>Disease Effect"]
A --> B
B --> C
C --> D
style A fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
style D fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9aNo linked papers recorded for this hypothesis yet.
No curated PDB or AlphaFold mapping for CLU yet. Search RCSB →
Median TPM across 13 brain regions for CLU (APOJ); VCP from GTEx v10.
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for CLU (APOJ); VCP.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF VCP-mutant astrocytes derived from patients with confirmed VCP mutations (p.R155H, p.R191Q, or p.A232E) are treated with 1μM CB-5083 (VCP/p97 activator) for 72 hours, THEN extracellular clusterin c | Extracellular clusterin concentration will reach ≥70% of wild-type levels (estimated baseline: 80-120 ng/mL for wild-type; target: ≥56-84 ng/mL for treated VCP- | — no observation — | pending | 0.65 |
| IF VCP-mutant astrocytes are cultured for 48 hours with 500 ng/mL recombinant human clusterin (rApoJ), THEN detergent-soluble TDP-43 fraction will increase by ≥25% relative to vehicle-treated VCP-muta | TDP-43 solubility will increase by ≥25% (measured as ratio of soluble:insoluble TDP-43 by sequential fractionation and immunoblot), reducing pathogenic aggregat | — no observation — | pending | 0.55 |